QTTB
NASDAQ HealthcareQ32 Bio Inc. - Common Stock
Biotechnology
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiยinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb ย CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
๐ Market Data
| Price | $9.24 |
|---|---|
| Volume | 560,877 |
| Market Cap | 273.28M |
| Beta | -0.380 |
| RSI (14-Day) | 11.2 Oversold |
| 200-Day MA | $8.52 |
| 50-Day MA | $14.21 |
| 52-Week High | $23.57 |
| 52-Week Low | $1.79 |
| P/E Ratio | 2.92 |
| Forward P/E | -9.00 |
| Price / Book | 2.06 |
๐ฏ Investment Strategy Scores
QTTB scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (67/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find QTTB in your text
Paste any article, transcript, or post โ the tool will extract QTTB and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-24.